Scroll to top

Gendius completes funding round led by Catapult Ventures

BioHub success as Gendius completes funding round led by Catapult Ventures to launch innovative digital health platform for patients living with diabetes

Alderley Park, UK – 5th  October 2017.

BioHub success, Gendius set up virtual tenancy at the BioHub about 2 years ago and then went through the various training days and mentoring programmes provided through the recent North of England Life Science Accelerator (NELSA programme). Since being in residence Gendius has had successful grant applications with Innovate UK and SBRI and this Venture Capital success comes on the back of pitching at one of the BioHub events. Ned Wakeman – Director at BioHub said “It is fantastic to see Gendius come through our programme and grow from the initial concept through to funding all under one roof. This is a great success story for the BioHub and will result in extra jobs based at the Park, and importantly, ultimately transforming the lives of patients with diabetes’.


Gendius was founded by Chris Genders and Rory Cameron with a view to making living with diabetes easier. The company has developed Intellin® – an App platform that uses an individual’s clinical history to predict those areas most likely of developing complications from their diabetes i.e. their individual high-risk areas. The platform then focusses the individual on clinically validated tasks and measures to slow their progression in these areas. The Intellin® platform is currently undergoing clinical trials and has won significant grant funding from both Innovate UK and the SBRI.


In addition to the investment, Chris Spencer, a Digital Health Advisor with Catapult Ventures, will join the board of Gendius as non-executive Chairman in early 2018. Until April 2017 Chris was CEO of EMIS Group Plc where he had held senior roles since 1999.


Chris Genders, CEO Gendius, said:

I’m extremely pleased to welcome the GM&C Life Sciences Fund as an investor in Gendius and welcome Chris as Chair elect. Chris’s wide-ranging experience in the leadership and management of healthcare technology businesses will be extremely valuable to Gendius as we seek to further enhance and commercialize our digital applications for diabetes and grow Gendius as a leader in this area.


Dr Vijay Barathan, Life Science Partner with Catapult Ventures said:

We are excited by this opportunity and fully support the approach Gendius is taking to develop a scalable and sustainable digital health business.


Chris Spencer, Digital Health Advisor with Catapult Ventures, said:

I am looking forward to working with Chris, Rory, and the team to fulfil the potential of their application to improve clinical outcomes in this area of high patient need and payer/provider cost.

Notes to Editors:

About BioHub at Alderley Park

BioHub at Alderley Park, operated by life science incubation specialist, The BioCity Group, supports the creation and growth of successful life science companies. This is achieved by creating the optimum environment for emerging businesses to thrive by offering 86,000sq ft of world class state-of-the-art laboratories and commercial office space, shared services, training, business support and access to investment.


About Gendius

Set up just over two years ago by Chris Genders and Rory Cameron our background is in Pharmaceuticals and Health Economics. We bring the disciplines of proving efficacy and value, through clinical trials and evidence, to the mobile health market. Our Intellin™ App based platform is designed with one thing in mind – Helping people live better with diabetes.

Chris, has taken his personal journey of living with diabetes and added this to his work with patient groups and healthcare professionals to develop a product that is individual and focusses on improving the development of future complications. Gendius in the last 12 months have won Innovate grant funding for a study in patients with Diabetic Foot Ulcers and in addition SBRI funding for a feasibility study in Gestational Diabetes.

Related posts